Raymond James Financial Inc. Takes $17.05 Million Position in Exelixis, Inc. (NASDAQ:EXEL)

Raymond James Financial Inc. acquired a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 511,879 shares of the biotechnology company's stock, valued at approximately $17,046,000. Raymond James Financial Inc. owned about 0.18% of Exelixis at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of EXEL. Principal Securities Inc. lifted its position in shares of Exelixis by 62.8% in the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 373 shares in the last quarter. USA Financial Formulas purchased a new stake in shares of Exelixis during the fourth quarter worth about $32,000. Kestra Investment Management LLC acquired a new position in shares of Exelixis in the fourth quarter valued at approximately $39,000. UMB Bank n.a. boosted its position in Exelixis by 68.4% during the fourth quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company's stock worth $45,000 after acquiring an additional 553 shares during the last quarter. Finally, V Square Quantitative Management LLC grew its stake in Exelixis by 37.3% in the 4th quarter. V Square Quantitative Management LLC now owns 1,563 shares of the biotechnology company's stock worth $52,000 after acquiring an additional 425 shares during the period. Institutional investors and hedge funds own 85.27% of the company's stock.

Exelixis Trading Down 0.6 %

EXEL stock traded down $0.22 on Friday, hitting $36.96. 7,275,510 shares of the company's stock traded hands, compared to its average volume of 2,092,892. The stock has a market cap of $10.34 billion, a price-to-earnings ratio of 20.88, a P/E/G ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a 1-year low of $20.14 and a 1-year high of $40.02. The stock has a fifty day moving average of $35.59 and a 200-day moving average of $32.74.

Remove Ads

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, equities research analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on EXEL. Piper Sandler upped their price objective on shares of Exelixis from $37.00 to $38.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. UBS Group increased their price target on shares of Exelixis from $30.00 to $34.00 and gave the stock a "neutral" rating in a research note on Tuesday, January 28th. JMP Securities restated a "market outperform" rating and issued a $41.00 price objective on shares of Exelixis in a report on Thursday, January 23rd. Truist Financial upped their target price on Exelixis from $42.00 to $43.00 and gave the stock a "buy" rating in a research report on Monday, January 27th. Finally, Morgan Stanley upgraded Exelixis from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $30.00 to $40.00 in a report on Monday, January 27th. One analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $37.59.

Insider Transactions at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 10,000 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $38.80, for a total transaction of $388,000.00. Following the sale, the executive vice president now directly owns 341,028 shares of the company's stock, valued at $13,231,886.40. The trade was a 2.85 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jack L. Wyszomierski sold 8,768 shares of the firm's stock in a transaction on Friday, February 28th. The stock was sold at an average price of $37.80, for a total value of $331,430.40. Following the completion of the sale, the director now directly owns 356,605 shares of the company's stock, valued at approximately $13,479,669. This trade represents a 2.40 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 140,343 shares of company stock valued at $5,177,234 over the last ninety days. Corporate insiders own 2.85% of the company's stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.